Altered O
resting-state O
functional O
connectivity O
of O
the O
cerebellum O
in O
schizophrenia O
Structural O
and O
functional O
abnormalities O
of O
the O
cerebellum O
in O
schizophrenia O
have O
been O
reported O
. O

Most O
previous O
studies O
investigating O
resting-state O
functional O
connectivity O
( O
rsFC O
) O
have O
relied O
on O
a O
priori O
restrictions O
on O
seed O
regions O
or O
specific O
networks O
, O
which O
may O
bias O
observations O
. O

In O
this O
study O
, O
we O
aimed O
to O
elicit O
the O
connectivity O
alterations O
of O
the O
cerebellum O
in O
schizophrenia O
in O
a O
hypothesis-free O
approach O
. O

Ninety-five O
schizophrenia O
patients O
and O
93 O
sex- O
and O
age-matched O
healthy O
controls O
underwent O
resting-state O
functional O
magnetic O
resonance O
imaging O
( O
fMRI O
) O
. O

A O
voxel-wise O
data-driven O
method O
, O
resting-state O
functional O
connectivity O
density O
( O
rsFCD O
) O
, O
was O
used O
to O
investigate O
cerebellar O
connectivity O
changes O
in O
schizophrenia O
patients O
. O

Regions O
with O
altered O
rsFCD O
were O
chosen O
as O
seeds O
to O
perform O
seed-based O
resting-state O
functional O
connectivity O
( O
rsFC O
) O
analyses O
. O

We O
found O
that O
schizophrenia O
patients O
exhibited O
decreased O
rsFCD O
in O
the O
right O
hemispheric O
VI O
; O
moreover O
, O
this O
cerebellar O
region O
showed O
increased O
rsFC O
with O
the O
prefrontal O
cortex O
and O
subcortical O
nuclei O
and O
decreased O
rsFC O
with O
the O
visual O
cortex O
and O
sensorimotor O
cortex O
. O

In O
addition O
, O
some O
rsFC O
changes O
were O
associated O
with O
positive O
symptoms O
. O

These O
findings O
suggest O
that O
abnormalities O
of O
the O
cerebellar O
hub O
and O
cerebellar-subcortical-cortical O
loop O
may O
be O
the O
underlying O
mechanisms O
of O
schizophrenia O
. O

Materials O
and O
methods O
Subjects O
Two O
hundred O
right-handed O
individuals O
were O
enrolled O
in O
this O
study O
, O
including O
98 O
schizophrenia O
patients O
and O
102 O
healthy O
controls O
. O

The O
Medical O
Research O
Ethics O
Committee O
of O
Tianjin O
Medical O
University O
General O
Hospital O
approved O
this O
study O
. O

After O
a O
complete O
description O
of O
the O
study O
, O
written O
informed O
consent O
was O
obtained O
from O
each O
subject O
. O

The O
diagnosis O
of O
schizophrenia O
was O
determined O
by O
the O
consensus O
of O
two O
experienced O
clinical O
psychiatrists O
using O
the O
Structured O
Interview O
for O
DSM-IV O
Axis O
I O
Disorders O
, O
Patient O
Edition O
( O
SCID-P O
) O
. O

Healthy O
controls O
were O
recruited O
from O
the O
local O
community O
via O
advertisements O
. O

All O
healthy O
controls O
were O
screened O
using O
the O
non-patient O
edition O
of O
the O
SCID O
( O
SCID-NP O
) O
to O
confirm O
a O
lifetime O
absence O
of O
psychiatric O
illnesses O
. O

In O
addition O
, O
all O
of O
the O
healthy O
controls O
were O
interviewed O
to O
exclude O
individuals O
with O
a O
known O
history O
of O
psychiatric O
illness O
in O
first-degree O
relatives O
. O

The O
exclusion O
criteria O
for O
all O
subjects O
were O
MRI O
contraindications O
, O
a O
history O
of O
head O
trauma O
with O
consciousness O
disturbances O
lasting O
more O
than O
five O
minutes O
, O
a O
history O
of O
drug O
or O
alcohol O
abuse O
, O
pregnancy O
, O
and O
any O
physical O
illness O
such O
as O
cardiovascular O
disease O
or O
neurological O
disorders O
, O
as O
diagnosed O
by O
an O
interview O
and O
medical O
records O
review O
. O

A O
professional O
radiologist O
assessed O
the O
image O
quality O
slice-by-slice O
, O
and O
three O
patients O
and O
9 O
healthy O
controls O
with O
poor O
image O
quality O
were O
excluded O
. O

Consequently O
, O
95 O
schizophrenia O
patients O
and O
93 O
healthy O
controls O
were O
included O
in O
the O
statistical O
analysis O
. O

The O
clinical O
symptoms O
of O
psychosis O
were O
quantified O
using O
the O
Positive O
and O
Negative O
Syndrome O
Scale O
( O
PANSS O
) O
. O

The O
antipsychotic O
dosages O
are O
reported O
as O
the O
chlorpromazine O
equivalents O
calculated O
based O
on O
clinically O
equivalent O
dosing O
estimates O
( O
Gardner O
et O
al O
. O
) O
. O

For O
each O
schizophrenia O
patient O
, O
the O
chlorpromazine O
equivalent O
was O
estimated O
according O
to O
the O
antipsychotic O
drugs O
and O
dosages O
used O
in O
the O
latest O
week O
before O
MRI O
. O

MRI O
data O
acquisition O
MRI O
data O
were O
acquired O
using O
a O
3.0-Tesla O
MR O
system O
( O
Discovery O
MR750 O
, O
General O
Electric O
, O
Milwaukee O
, O
WI O
, O
USA O
) O
. O

Tight O
but O
comfortable O
foam O
padding O
was O
used O
to O
minimize O
head O
motion O
, O
and O
earplugs O
were O
used O
to O
reduce O
scanner O
noise O
. O

Sagittal O
3D O
T1-weighted O
images O
were O
acquired O
using O
a O
brain O
volume O
sequence O
and O
the O
following O
parameters O
: O
repetition O
time O
( O
TR O
) O
= O
8.2 O
ms O
; O
echo O
time O
( O
TE O
) O
= O
3.2 O
ms O
; O
inversion O
time O
( O
TI O
) O
= O
450 O
ms O
; O
flip O
angle O
( O
FA O
) O
= O
12° O
; O
field O
of O
view O
( O
FOV O
) O
= O
256 O
mm O
× O
256 O
mm O
; O
matrix O
=256 O
× O
256 O
; O
slice O
thickness O
= O
1 O
mm O
, O
no O
gap O
; O
and O
188 O
sagittal O
slices O
. O

Resting-state O
fMRI O
data O
were O
acquired O
using O
a O
gradient-echo O
single-short O
echo O
planar O
imaging O
sequence O
with O
the O
following O
parameters O
: O
TR/TE O
= O
2000/45 O
ms O
; O
FOV O
= O
220 O
mm O
× O
220 O
mm O
; O
matrix O
=64 O
× O
64 O
; O
FA O
= O
90° O
; O
slice O
thickness O
= O
4 O
mm O
; O
gap O
=0.5 O
mm O
; O
32 O
interleaved O
transverse O
slices O
; O
and O
180 O
volumes O
. O

All O
subjects O
were O
instructed O
to O
keep O
their O
eyes O
closed O
, O
relax O
, O
move O
as O
little O
as O
possible O
, O
think O
of O
nothing O
in O
particular O
, O
and O
not O
fall O
asleep O
during O
the O
fMRI O
scans O
. O

fMRI O
data O
preprocessing O
Resting-state O
fMRI O
data O
were O
preprocessed O
using O
SPM8 O
( O
http O
: O
//www.fil.ion.ucl.ac.uk/spm O
) O
. O

The O
first O
10 O
volumes O
for O
each O
subject O
were O
discarded O
to O
allow O
the O
signal O
to O
reach O
equilibrium O
and O
the O
participants O
to O
adapt O
to O
the O
scanning O
noise O
. O

The O
remaining O
volumes O
were O
corrected O
for O
the O
acquisition O
time O
delay O
between O
slices O
. O

Next O
, O
realignment O
was O
performed O
to O
correct O
the O
motion O
between O
time O
points O
. O

All O
of O
the O
subjects O
’ O
fMRI O
data O
were O
within O
the O
defined O
motion O
thresholds O
( O
i.e. O
, O
translational O
or O
rotational O
motion O
parameters O
less O
than O
2 O
mm O
or O
2° O
) O
. O

We O
also O
calculated O
frame-wise O
displacement O
( O
FD O
) O
, O
which O
indexes O
the O
volume-to-volume O
changes O
in O
head O
position O
. O

There O
were O
no O
significant O
group O
differences O
in O
FD O
( O
t O
= O
0.56 O
, O
P O
= O
0.58 O
) O
between O
the O
patients O
( O
0.117 O
± O
0.007 O
) O
and O
controls O
( O
0.113 O
± O
0.006 O
) O
. O

Several O
nuisance O
covariates O
( O
six O
motion O
parameters O
, O
their O
first-time O
derivations O
, O
and O
average O
BOLD O
signals O
of O
the O
ventricular O
and O
white O
matter O
) O
were O
regressed O
out O
from O
the O
data O
. O

Recent O
studies O
have O
reported O
that O
the O
signal O
spike O
caused O
by O
head O
motion O
significantly O
contaminated O
the O
final O
resting-state O
fMRI O
results O
even O
after O
regressing O
out O
the O
linear O
motion O
parameters O
( O
Power O
et O
al O
. O
) O
. O

Therefore O
, O
we O
further O
regressed O
out O
spike O
volumes O
when O
the O
FD O
of O
the O
specific O
volume O
exceeded O
0.5 O
. O

The O
datasets O
were O
then O
band-pass O
filtered O
in O
a O
frequency O
range O
of O
0.01 O
to O
0.08 O
Hz O
. O

In O
the O
normalization O
step O
, O
individual O
structural O
images O
were O
linearly O
co-registered O
with O
the O
mean O
functional O
image O
; O
the O
transformed O
structural O
images O
were O
segmented O
into O
gray O
matter O
, O
white O
matter O
, O
and O
cerebrospinal O
fluid O
. O

The O
gray O
matter O
maps O
were O
non-linearly O
transformed O
to O
the O
tissue O
probability O
maps O
in O
the O
Montreal O
Neurological O
Institute O
( O
MNI O
) O
space O
. O

Finally O
, O
each O
filtered O
functional O
volume O
was O
spatially O
normalized O
to O
the O
MNI O
space O
using O
the O
parameters O
estimated O
during O
the O
non-linear O
transformation O
and O
resampled O
into O
a O
3-mm O
cubic O
voxel O
. O

rsFCD O
calculation O
and O
analysis O
The O
rsFCD O
of O
each O
voxel O
was O
calculated O
using O
an O
in-house O
script O
that O
was O
written O
in O
the O
Linux O
platform O
according O
to O
the O
method O
described O
by O
Tomasi O
and O
Volkow O
( O
Tomasi O
and O
Volkow O
) O
. O

Pearson O
’ O
s O
linear O
correlation O
evaluated O
the O
strength O
of O
the O
functional O
connectivity O
between O
every O
pair O
of O
voxels O
in O
the O
entire O
brain O
. O

Two O
voxels O
with O
a O
correlation O
coefficient O
, O
which O
was O
larger O
than O
a O
predefined O
threshold O
, O
were O
considered O
to O
be O
significantly O
connected O
. O

To O
obtain O
reliable O
and O
robust O
results O
, O
we O
used O
multiple O
threshold O
levels O
( O
R O
= O
0.4 O
, O
0.6 O
and O
0.8 O
) O
to O
compute O
the O
rsFCD O
. O

The O
rsFCD O
calculation O
was O
restricted O
to O
a O
whole O
brain O
mask O
including O
the O
cerebellum O
. O

The O
rsFCD O
at O
a O
given O
voxel O
x0 O
was O
computed O
as O
the O
total O
functional O
connectivity O
, O
k O
( O
x0 O
) O
, O
between O
x0 O
and O
all O
other O
voxels O
. O

This O
calculation O
was O
repeated O
for O
all O
voxels O
within O
the O
whole O
brain O
mask O
. O

To O
increase O
the O
normality O
of O
the O
distribution O
, O
grand O
mean O
scaling O
was O
performed O
by O
dividing O
the O
rsFCD O
of O
each O
voxel O
by O
the O
mean O
value O
of O
the O
whole O
brain O
. O

Finally O
, O
the O
rsFCD O
maps O
were O
spatially O
smoothed O
using O
a O
6 O
mm O
× O
6 O
mm O
× O
6 O
mm O
full-width O
at O
half O
maximum O
( O
FWHM O
) O
Gaussian O
kernel O
. O

Inter-group O
differences O
in O
rsFCD O
were O
voxel-wisely O
compared O
within O
a O
cerebellar O
mask O
using O
a O
general O
linear O
model O
with O
age O
and O
sex O
as O
nuisance O
variables O
. O

Correction O
for O
multiple O
comparisons O
was O
performed O
using O
the O
voxel-level O
false O
discovery O
rate O
( O
FDR O
) O
method O
with O
a O
corrected O
threshold O
of O
P O
< O
0.05 O
. O

The O
significant O
regions O
in O
3 O
comparisons O
( O
corresponding O
to O
the O
three O
thresholds O
) O
were O
overlapped O
. O

The O
overlapping O
areas O
were O
identified O
as O
the O
regions O
of O
interest O
( O
ROIs O
) O
for O
the O
correlation O
analyses O
and O
were O
defined O
as O
seed O
regions O
for O
the O
subsequent O
rsFC O
analyses O
. O

The O
ROI-based O
correlation O
analyses O
with O
the O
clinical O
variables O
, O
including O
antipsychotic O
dosages O
of O
chlorpromazine O
equivalents O
, O
illness O
duration O
and O
PANSS O
scores O
, O
were O
performed O
for O
the O
patient O
group O
using O
partial O
correlation O
analysis O
with O
age O
and O
sex O
as O
the O
nuisance O
covariates O
. O

For O
these O
correlation O
analyses O
, O
a O
significant O
threshold O
was O
set O
at O
P O
< O
0.05. O
rsFC O
analysis O
Most O
of O
the O
data O
preprocessing O
steps O
for O
the O
rsFC O
analysis O
were O
the O
same O
as O
the O
preprocessing O
steps O
for O
the O
rsFCD O
calculation O
. O

The O
only O
difference O
was O
that O
functional O
images O
were O
smoothed O
using O
a O
Gaussian O
kernel O
of O
6 O
mm O
× O
6 O
mm O
× O
6 O
mm O
FWHM O
after O
normalization O
. O

For O
each O
subject O
, O
Pearson O
’ O
s O
correlation O
coefficients O
between O
the O
mean O
time O
series O
of O
the O
seed O
region O
and O
that O
of O
each O
voxel O
in O
the O
whole O
brain O
was O
computed O
and O
converted O
to O
z-values O
using O
Fisher O
’ O
s O
r-to-z O
transformation O
to O
improve O
the O
normality O
. O

Next O
, O
the O
individual O
’ O
s O
z-values O
were O
entered O
into O
a O
random-effects O
one-sample O
t-test O
in O
a O
voxel-wise O
manner O
using O
SPM8 O
. O

FDR O
correction O
with O
P O
< O
0.05 O
was O
used O
to O
identify O
brain O
regions O
that O
showed O
significant O
positive O
correlations O
with O
the O
seed O
region O
. O

Next O
, O
a O
two-sample O
t-test O
was O
performed O
within O
the O
positive O
rs-FC O
mask O
to O
quantitatively O
compare O
the O
differences O
in O
rsFC O
of O
the O
seed O
region O
between O
schizophrenia O
patients O
and O
healthy O
controls O
. O

Multiple O
comparisons O
were O
corrected O
using O
the O
FDR O
method O
with O
a O
corrected O
threshold O
of O
P O
< O
0.05 O
. O

To O
test O
the O
association O
between O
rsFC O
and O
the O
clinical O
variables O
, O
voxel-wise O
multiple O
regression O
analysis O
was O
performed O
for O
the O
patient O
group O
within O
a O
mask O
constructed O
from O
the O
group O
differences O
between O
patients O
and O
controls O
. O

A O
threshold O
of O
P O
< O
0.01 O
was O
considered O
significant O
. O

